BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 27137106)

  • 1. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome.
    Baskind NE; Balen AH
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():80-97. PubMed ID: 27137106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    Blank SK; McCartney CR; Helm KD; Marshall JC
    Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology.
    Balen A
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):685-706. PubMed ID: 15380141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of Hypothalamic-Pituitary-Adrenal Axis and Hypothalamus-Pituitary-Ovary Axis in the Abnormal Endocrine Functions in Patients with Polycystic Ovary Syndrome.
    Wang F; Zhang ZH; Xiao KZ; Wang ZC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Oct; 39(5):699-704. PubMed ID: 29125115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome.
    Blank SK; McCartney CR; Marshall JC
    Hum Reprod Update; 2006; 12(4):351-61. PubMed ID: 16670102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP; Lu JK; Chang RJ
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. La esteroidogénesis en el síndrome de ovarios poliquísticos.
    Ventura-Arizmendi E; Hernández-Valencia M
    Gac Med Mex; 2019; 155(2):184-190. PubMed ID: 31056603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive endocrinology of adolescent polycystic ovary syndrome.
    Shayya R; Chang RJ
    BJOG; 2010 Jan; 117(2):150-5. PubMed ID: 20002395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.
    Jonard S; Dewailly D
    Hum Reprod Update; 2004; 10(2):107-17. PubMed ID: 15073141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).
    Li Y; Chen C; Ma Y; Xiao J; Luo G; Li Y; Wu D
    Life Sci; 2019 Jul; 228():167-175. PubMed ID: 31029778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome.
    Dafopoulos K; Venetis C; Pournaras S; Kallitsaris A; Messinis IE
    Fertil Steril; 2009 Oct; 92(4):1378-1380. PubMed ID: 19467538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic ovary syndrome in adolescent girls.
    Baldauff NH; Witchel SF
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):56-66. PubMed ID: 27906711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine control in polycystic ovary-like syndrome.
    Schoemaker J
    Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis.
    Azziz R; Black V; Hines GA; Fox LM; Boots LR
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.
    Barnes RB
    J Endocrinol Invest; 1998 Oct; 21(9):567-79. PubMed ID: 9856411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological pulses in PCOS.
    Coyle C; Campbell RE
    Mol Cell Endocrinol; 2019 Dec; 498():110561. PubMed ID: 31461666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Etiopathogenesis of the polycystic ovary syndrome].
    Sciarra F; Toscano V; Tosti-Croce C
    Minerva Endocrinol; 1987; 12(3):183-90. PubMed ID: 3116379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.